Education
About Us
Working with TipRanks
Follow Us
Opko Health (OPK)
:OPK
OPK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.86 - $1.84
Previous CloseN/A
Volume574.71K
Average Volume (3M)3.24M
Market Cap
$1.19B
Enterprise Value$1.59B
Total Cash (Recent Filing)$96.47M
Total Debt (Recent Filing)$31.60M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
May 13, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding682,483,030
10 Day Avg. Volume4,270,120
30 Day Avg. Volume3,239,489
Standard Deviation0.21
R-Squared0.17
Alpha0.00088
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.67
Price to Cash Flow (P/CF)2.10
P/FCF Ratio2.20
Enterprise Value/Market Cap1.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.01
Enterprise Value/Ebitda84.08
Forecast
1Y Price Target
$2.75Price Target Upside58.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Opko Health News
PremiumCompany Announcements
OPKO Health’s Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
OPKO Health Reports Strategic Advances and Financial Turnaround
PremiumCompany Announcements
OPKO Health to Announce Q4 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOPKO delivered a solid Q4/24 result, with fourth quarter top-line performance easily exceeding expectations.
Strategic PartnershipsModeX Therapeutics entered into an exclusive worldwide license and collaboration agreement with Merck for the development of MDX-2201—a preclinical nanoparticle vaccine candidate targeting the Epstein-Barr virus.
Bears Say
Revenue PerformanceConsolidated total revenues were $173.6M, representing 3% YoY decline and missing our projection of $181M.
---
Ownership Overview
51.37% Insiders
6.38% Mutual Funds
9.25% Other Institutional Investors
21.45% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OPK FAQ
What was Opko Health’s price range in the past 12 months?
Opko Health lowest stock price was $0.86 and its highest was $1.84 in the past 12 months.
What is Opko Health’s market cap?
Opko Health’s market cap is $1.19B.
When is Opko Health’s upcoming earnings report date?
Opko Health’s upcoming earnings report date is May 13, 2025 which is in 70 days.
How were Opko Health’s earnings last quarter?
Opko Health released its earnings results on Feb 27, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.093 by $0.103.
Is Opko Health overvalued?
According to Wall Street analysts Opko Health’s price is currently Undervalued.
Does Opko Health pay dividends?
Opko Health does not currently pay dividends.
What is Opko Health’s EPS estimate?
Opko Health’s EPS estimate is -0.09.
How many shares outstanding does Opko Health have?
Opko Health has 682,483,030 shares outstanding.
What happened to Opko Health’s price movement after its last earnings report?
Opko Health reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.093. Following the earnings report the stock price went up 6.748%.
Which hedge fund is a major shareholder of Opko Health?
Currently, no hedge funds are holding shares in OPK
---
Opko Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.75 (58.05% Upside)
$2.75 (58.05% Upside)
Blogger Sentiment
Bullish
OPK Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 62.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.64%
12-Months-Change
Fundamentals
Return on Equity
-3.87%
Trailing 12-Months
Asset Growth
9.37%
Trailing 12-Months
Company Description
Opko Health
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
---
OPK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in the ModeX pipeline, successful global commercialization efforts for NGENLA, and substantial additional funding from BARDA for antiviral programs. However, these positive developments were tempered by a decline in Diagnostics segment revenue and operating losses, as well as increased R&D expenses and foreign currency challenges. Overall, the highlights slightly outweigh the lowlights.Read More>---
OPK Stock 12 Month Forecast
Average Price Target
$2.75
▲(58.05% Upside)
Technical Analysis
Best Analysts Covering OPK
1 Year
1 Year Success Rate
17/38 ratings generated profit
1 Year Average Return
+13.51%
reiterated a buy rating 4 days ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 44.74% of your transactions generating a profit, with an average return of +13.51% per trade.
---